Whereas the opioid epidemic continues to devastate communities across the United States, leading to a significant loss of life and widespread societal impact; Whereas, as of December 2022, opioid overdoses during the previous 12 months claimed a reported 79,770 lives in the United States; Whereas fatal overdoses are often witnessed by a bystander; Whereas, in 2022 alone, the Drug Enforcement Administration seized more than 379,000,000 doses of potentially deadly fentanyl, enough to kill every individual in the United States; Whereas, according to data from the Centers for Disease Control and Prevention, fentanyl-related poisonings are currently the leading cause of death for individuals in the United States between 18 and 49 years of age; Whereas naloxone is a safe and effective medication that can reverse opioid overdoses and save lives when administered promptly by rapidly reversing the effects of opioids; Whereas naloxone plays a vital role in preventing long-term brain damage and reducing the risk of fatality associated with opioid overdoses; Whereas the Centers for Disease Control and Prevention has declared naloxone to be a key tool in preventing opioid overdose deaths; Whereas it is imperative to educate individuals, families, healthcare professionals, and first responders about— (1) the benefits of naloxone, including the potential naloxone has to reduce opioid-related fatalities; and (2) how to administer naloxone; Whereas it is imperative to identify current or potential barriers, including cost, for individuals, organizations, and Federal, State, and local governments to obtain and distribute naloxone; Whereas increasing access to naloxone can ensure that individuals struggling with opioid use disorder have a chance at recovery and a future free from the grip of substance use disorder; Whereas the Food and Drug Administration took action to authorize the over-the-counter sale of 4 milligram doses of naloxone